Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Abstracts are available on the EASL Congress 2025 website at https://www.easlcongress.eu/. The posters are expected to be ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Fatigue and yellowing eyes may signal hepatitis, a serious liver issue. Learn the symptoms, causes, prevention, and available ...

Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...

with nearly all subjects developing hepatitis A antibodies (anti-HAV) within 2 weeks. [3] However, a second dose of vaccine, given 6 or 12 to 18 months after the first dose in accordance with the ...

Over 300 cases of hepatitis A have been reported so far ... has resulted in a growing number of people without protective antibodies who are highly susceptible to infection. This mainly concerns ...

Hepatitis A and hepatitis E are viral infections ... Although a study looking at HEV antibodies in Americans could not determine exposure, many cases of HEV in the U.S. involve people who have ...

The good news is that once you recover from hepatitis A, you develop antibodies that protect you from the virus for life, according to the U.S. Centers for Disease Control and Prevention.

MONDAY, April 21, 2025 (HealthDay News) — Key labs at the U.S. Centers for Disease Control and Prevention (CDC) have shut ...